AEterna Zentaris Subsidiary Atrium Biotechnologies Acquires Canadian Business Multichem

AEterna Zentaris has announced the closing of the acquisition of all Multichem assets by its subsidiary Atrium Biotechnologies for the total amount of $23.8 million of which $22.2 million were paid in cash at the closing. This acquisition was financed through Atrium's working capital, as well as from a new banking credit facility. Multichem is a privately held Canadian company specialized in the marketing of active ingredients and specialty chemicals.

CanadaIT.com (http://www.canadait.com/cfm/index.cfm?It=106&Id=21551&Se=0&Lo=2)